New drug combo aims to halt artery plaque after heart attacks
NCT ID NCT07612774
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests whether adding evolocumab, a cholesterol-lowering drug, to standard care can slow or stop plaque buildup in heart arteries after a heart attack. About 233 adults aged 40-75 who recently had a heart attack or unstable angina will receive either evolocumab plus standard therapy or standard therapy alone. Researchers will use advanced CT scans at the start and after 52 weeks to measure changes in plaque volume and artery narrowing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Evolocumab
What this could lead to
If it works, this could show that adding evolocumab to standard therapy slows or stops plaque buildup in heart arteries, potentially reducing future heart attack risk.
What could go wrong
This is a single-center, open-label trial with 233 participants, so results may not apply broadly. The study is early-stage for this specific combination, and evolocumab can cause side effects like injection site reactions or muscle pain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.